www.hivandhepatitis.com

Back HCV Treatment

Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)

Details
Category: Experimental HCV Drugs
Published on Friday, 01 May 2009 13:47
Written by Liz Highleyman
  • Print

At the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last week in Copenhagen, Denmark, researchers presented data from PROVE3, a Phase 2b study of 453 genotype 1 chronic hepatitis C patients in the U.S. and Europe who did not achieve sustained response with a prior course of pegylated interferon plus ribavirin.

Read more:

Subcategories

Copyright © 2026 www.hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com. Joomla! is Free Software released under the GNU General Public License.

Bread and Roses Web DesignWeb Design and Development by Bread and Roses Web Design